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concern not only in the United States, but throughout the world. The wide-spread use of radiotherapy for 
head and neck cancer as well as bone antiresorptives and antiangiogenic agents have increased the 
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clearly defined, there has been a much higher incidence of medication-related osteonecrosis of the jaw 
relative to the other types of osteonecrosis. The traditional osteoradionecrosis still occurs despite better 
treatment planning and shielding to minimize collateral damage to bone. There are other related necrotic 
lesions secondary to usage of recreation drugs and the use of steroids. This chapter will give 
comprehensive information about these different types of bone necrosis; provide the readers with 
radiographic diagnostic criteria and updates on current theories on pathophysiology of osteonecrosis. 
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Chemical and Radiation Associated Jaw Lesions
Temitope T. Omolehinwa, BDS and Sunday O. Akintoye, BDS, DDS, MS
Synopsis
Osteonecrosis of the jaw, at one time considered to be infrequent has now become a major public 
health concern not only in the United States, but throughout the world. The wide-spread use of 
radiotherapy for head and neck cancer as well as bone antiresorptives and antiangiogenic agents 
have increased the incidence of osteonecrosis. While the exact pathophysiological process of 
osteonecrosis is yet to be clearly defined, there has been a much higher incidence of medication-
related osteonecrosis of the jaw relative to the other types of osteonecrosis. The traditional 
osteoradionecrosis still occurs despite better treatment planning and shielding to minimize 
collateral damage to bone. There are other related necrotic lesions secondary to usage of recreation 
drugs and the use of steroids. This chapter will give comprehensive information about these 
different types of bone necrosis; provide the readers with radiographic diagnostic criteria and 
updates on current theories on pathophysiology of osteonecrosis.
Keywords
Osteoradionecrosis; Medication-related Osteonecrosis; chemical; radiation; recreational drug; 
Damage; Diseases; Necrosis
1. Introduction
Bone is a unique connective tissue because it is functionally dynamic, consisting of different 
cells that continuously interact together. Unlike other connective tissues within the body, 
bone is physiologically mineralized. There is also an abundance of osteoprogenitor cells that 
reside within the bone microenvironment that can be activated to form different cell types 1. 
The ability of bone to constantly remodel plays a vital role in the maintenance of mineral 
homeostasis as old bone is removed by the activities of osteoclasts and new bone matrix is 
deposited by osteoblasts. Essentially, external and internal insults from radiation, drugs or 
other chemical insults can induce a pathological process that disrupts the bone 
microenvironment, turnover and homeostasis. The outcome is dysregulation of the bone 
healing process that can potentially lead to loss of bone tissue as in osteonecrosis.
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Osteonecrosis is characterized by tissue dehiscence, chronic bone devitalization, 
hypocellularity and osteolysis. The term osteonecrosis is often used interchangeably with 
ischemic necrosis, avascular necrosis or aseptic necrosis but there are different types of 
osteonecrosis. Depending on the etiological agent, osteonecrosis can occur in any bone 
including the orofacial, appendicular and axial bones. Osteonecrosis may or may not be 
associated with exposed bone with delayed healing. Specifically, the femoral head and 
mandible are highly susceptible to osteonecrosis. In the orofacial region, jaw osteonecrosis 
can lead to significant loss of bone tissue, tooth loss and facial disfigurement. The 
unfortunate outcomes are significant morbidity, debility and diminished quality of life 2. The 
high susceptibility of the femoral bone to osteonecrosis is associated with a variety of 
factors that include alcohol abuse and steroid therapy. However, jaw osteonecrosis is much 
more associated with complications of radiation therapy, and long term therapy with bone 
antiresorptives used to control skeletal events of cancer metastasis and osteoporosis 3, 4. In a 
randomized controlled study that assessed 792 cases of osteonecrosis in general, 76% of the 
cases occurred in the hip while 4.4% occurred in the jaw mainly as a result of 
bisphosphonate therapies. The remaining cases were associated with either the wrist, knee, 
foot or ankle 5. Several pathophysiologic theories have been proposed for osteonecrosis 
based on correlations of clinical signs with histologic and radiologic analyses. Although 
many of these theories have not been conclusively established, radiographic imaging has 
played a major role in the diagnosis, management and follow up assessment of 
osteonecrosis. Even more importantly, is the increasing use of the combination of functional 
imaging with planar images to fully understand the metabolic changes that lead to 
osteonecrosis 6.
2. Types of osteonecrosis
Osteoradionecrosis
Osteoradionecrosis (ORN) of the jaw is defined as non-healing bony exposure and necrosis 
that starts with a breach in the oral mucosa, and persists for at least 3 months in a patient that 
has undergone previous radiation therapy. The necrosis however, must be evidently different 
from a recurrent, vestigial or metastatic tumor 7, 8. This definition however does not include 
cases of ORN in which the oral mucosa is intact, but osteonecrotic changes can be observed 
by diagnostic imaging 9. ORN is a chronic condition that can last for months or even years 
after the initial radiation therapy. The incidence of ORN can range from 2.6 - 22% 10 and it 
develops when the radiation dose exceeds 50 Gy. Specifically, radiation doses between 
50-70Gy have been implicated in the etiology of ORN 11. Within the orofacial complex, the 
mandible is commonly affected because the mandible is usually in the line of radiation 
delivery and it is believed that the mandible is less vascularized than the maxilla 12, 13. 
Radiation also affects teeth secondarily due to pronounced xerostomia noted in patients 
receiving radiation therapy (fig 1). The extensive carious lesions can be readily noted on 
radiographs as demonstrated in these bitewings (figs 2, 3)
Pathogenesis—Osteoradionecrosis was first described in 1926 14. It was not until 1970 
that a triad of radiation, trauma and infection was proposed as the mechanistic process in 
ORN. However, this theory was later replaced in 1983 by another proposal that radiation 
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causes development of hypoxic-hypocellular-hypovascular tissue (3H theory) 15 when it was 
reported that microorganisms do not play any causative but rather a contaminant role in 
ORN. It was also reported that trauma mainly creates a portal of entry for microorganisms to 
invade the radiation-suppressed bone. The 3H theory of ORN takes into account that several 
tissues from exterior to interior are damaged by radiation ranging from the skin or mucosa to 
periosteum, bone and finally endothelium within the bone marrow compartment 16. So the 
combination of tissue fibrosis, vascular and cellular damage induces a hypoxic environment 
within the radiated tissue 16. The 3H theory was quickly followed by development of 
hyperbaric oxygen (HBO) therapy protocols to prevent and treat ORN, but this had only 
modest effectiveness and HBO therapy is limited because it is contraindicated in patients 
with metastatic cancer 3, 4, 17.
The radiation induced fibroatrophic process is another mechanism associated with radiation 
damage more commonly to the superficial structures. This is associated with the activity of 
reactive oxygen species that cause damage to fibroblasts, endothelium and bone cells 
eventually causing tissue and bone necrosis (fig 4). However, the direct application of this 
theory to deep seated radiation damage within the bone is yet to be conclusively clarified 16. 
Another proposed pathophysiologic hypothesis is that ORN can be precipitated by a 
combination of dysregulated turnover, osteoclast depletion, local tissue injury and 
infection 11. As all these theories do not conclusively define the pathophysiological process 
of ORN, more work is still needed to further our understanding of ORN pathogenesis.
Risk factors and classification—Several risk factors predispose to ORN; these include 
poor oral health, smoking, alcohol abuse and most importantly type and dose of radiation. 
Brachytherapy and radiation doses greater than 50 Gy have been associated with higher 
incidence of ORN. Additionally, any surgical manipulations of the irradiated area including 
dental extractions pose a significant risk. Several different classification of ORN have been 
proposed, but one recently proposed theory combines clinical description, presence or 
absence of symptoms and the treatment option for each of the different stages of ORN 
(Table 1) 9.
Clinical presentation—ORN patients usually present with pain, typically neuropathic in 
nature, swelling and may be accompanied by fever depending on the extent of the 
inflammatory process. Follow up clinical evaluation may reveal tissue breakdown and bone 
necrosis that may be accompanied by paresthesia/anesthesia. If untreated, ORN especially in 
the mandible may result in pathological fracture. Definitive diagnosis of ORN is a 
combination of clinical, radiologic and histologic evaluations.
Medication-Related Osteonecrosis of the Jaws
Medication related osteonecrosis of the jaw (MRONJ) is a more recent class of jaw 
osteonecrosis first described in 2003 in patients taking nitrogen-containing 
bisphosphonates 18. It is defined as exposed bone in the intraoral cavity persisting for 8 
weeks or more, in patients that have previously undergone, or are currently undergoing 
treatment with antiresorptives and/or antiangiogenic agents and with no prior history of 
radiation therapy to the jaw. This excludes primary or metastatic cancer within the jaw 
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region (Ruggiero et al. 2014). However, this definition does not take into account the non-
exposed bone variant of the disease process, which makes up about a third of all cases of 
MRONJ cases 19.
Nitrogen containing bisphosphonates (nBP) especially the intravenous nBP such as 
zoledronic acid were the first group of drugs initially associated with MRONJ. The high 
efficacy of intravenous nBP such as zoledronic acid and pamidronate to control altered bone 
remodeling make them highly favored for the treatment of skeletal events of cancer 
metastasis, Paget's disease, osteogenesis imperfecta and hyperparathyroid jaw tumors, so it 
is understandable that nBP were the first to be associated with osteonecrosis exclusive to the 
jaws. Other medication have also been implicated in MRONJ; these include another 
antiresorptive drug, denosumab that acts as an inhibitor of receptor activator for NFκB 
ligand (RANKL) and anti-angiogenic drugs like bevacizumab, an inhibitor of VEGF and 
sunitinib, a tyrosine kinase inhibitor.
Due to the vast array of medications associated with osteonecrosis of the jaw (ONJ), the 
nomenclature for this disorder has evolved over the years from ONJ, BON, BRONJ and 
ARONJ to the more recent MRONJ 20. The incidence of MRONJ in patients taking 
intravenous nBP ranges from 0 - 27.5% 19, 20, denosumab 1.7% 19.The relative risk of 
MRONJ occurring in patients taking intravenous nBP, denosumab or bevacizumab are 0.7- 
6.7%, 0.7 – 1.9% and 0.2% respectively 20. MRONJ affects the mandible and maxilla at a 
ratio of 2: 1 21 because the mandible is partly associated with a single vascular supply from 
the inferior alveolar artery compared to the superior, inferior and middle arteries in the 
maxilla. Severe cases of MRONJ in the mandible can lead to pathological fracture while in 
the maxilla it can result in oro-antral fistulation.
Pathogenesis—The pathophysiology of MRONJ is still unclear but different investigators 
have proposed several theories 22, 23. These include a decrease in bone turnover; presence of 
infection (especially Actinomyces species); inhibition of angiogenesis; and a dysregulation 
or dysfunction of innate and acquired immunity 24. The infection theory is based on the 
premise that a “complex biofilm” is present on the surface of exposed necrotic bone 25. 
Definitive elucidation of MRONJ pathogenesis is hampered by the fact that the offending 
drugs have different mechanisms of action (see Table 2) and non-oral bones are spared by 
MRONJ. The role of bone mesenchymal stem (MSCs) can also not be overlooked 
considering that jaw MSCs are phenotypically and functionally different from those of axial 
and appendicular bones 1 and are disproportionately more sensitive to both zoledronic acid 
and pamidronate both of which are strongly associated with MRONJ 26.
Risk factors and classification—The local risk factors that may predispose to MRONJ 
include trauma, overall poor dental health, presence of tori or bony exostosis, and invasive 
dental procedures such as dental extractions and periodontal treatment. In addition, the 
systemic risk factors include diabetes, smoking, alcohol and an ongoing immunosuppressive 
therapy 28.
Clinical presentation—Patients with MRONJ have variable clinical presentation 
depending on the clinical course of the disease. This can vary from non-exposed bone to 
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extensive bone loss and pathological fracture (fig 5). Therefore, a staging algorithm has been 
proposed to aid not only in the diagnosis but also management of MRONJ (see table 3). A 
detailed history, clinical examination and carefully selected radiographic imaging will aid in 
the diagnosis of MRONJ. (figs 6-7)
Recreational drug induced osteonecrosis
Chronic use of recreational or illicit drugs such as cocaine, amphetamine and 
methamphetamine are established independent risk factors for osteonecrosis, termed 
Recreational drug induced osteonecrosis (RDIO) 29-32. It is more common in the maxilla 29. 
The incidence of recreational drug induced osteonecrosis is unknown because many addicts 
do not seek medical care. Additionally, most illicit drug addicts are also heavy smokers and 
may be abusing alcohol or other prescription drugs, which also heightens their 
predisposition to osteonecrosis 31. The pathogenesis of RDIO is multifactorial. Although 
several recreational drugs have been implicated, cocaine in particular induces vascular 
constriction that results in local ischemia of the adjacent soft and hard tissues 33. It has been 
proposed that the combined effect of chemical irritation from additives to the recreational 
drug, trauma and superimposed microbial infection accentuate the necrotic process that 
leads to bone destruction 32. Therefore, excessive bone destruction caused by nasal 
inhalation or snorting of a recreational drug like cocaine initially starts as ulceration of 
mucosal tissue that progressively leads to osteocartilaginous necrosis. If uncontrolled, the 
nasal septum and palate become perforated consequently leading to oro-nasal and oro-antral 
fistulations 30, 34. Specifically, cocaine-induced midline destructive lesion (CIMDL) has 
been used to describe extensive destruction caused by cocaine addiction to the oro-nasal 
structures including the hard palate 32. This extensive osteonecrosis of the bony structures is 
one of the hallmarks used to identify CIMDL in the assessment of human skeletal remains 
by medical examiners and forensic scientists. If the addicted individual seeks treatment 
early, which often does not happen, RDIO can be controlled before extensive bone 
destruction occurs by discontinuation of the offending recreational drug
Steroid Induced Osteonecrosis
Steroid induced osteonecrosis also referred to as aseptic, ischemic, or avascular necrosis 
develops as a result of long-term administration of corticosteroids. It is more common in the 
appendicular bones such as the femur or humerus rather than the jaw35, 36 and it is not 
induced by trauma or external insults, so it is a form of atraumatic osteonecrosis. 
Corticosteroids affects multiple organs and systems, it has immunosuppressive effects and 
can disrupt bone homeostasis 36. Long-term use of corticosteroids for more than 20 mg per 
day can result in osteopenia and eventually osteoporosis. To further complicate the situation, 
the patient may need to be placed on bisphosphonate therapy to control dysregulated bone 
remodeling, consequently resulting in the development of medication-induced osteonecrosis 
of the jaw. Smoking, alcohol abuse and comorbid conditions like osteoporosis and systemic 
lupus erythematosus predispose patients to steroid induced osteonecrosis. 37
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3. Histological features of osteonecrosis
Definitive diagnosis of osteonecrosis is based on clinical, histological and radiological 
findings. Histologically, vascular damage with hyperemia, inflammatory cells and 
osteoclastic activity are often seen at the early stages of osteonecrosis. Thereafter, 
osteonecrosis displays regions of acellular marrow with loss of hematopoietic cells, 
adipocytic infiltration suggestive of fatty marrow and some regions of patchy calcifications 
within the marrow components due to osteoclastic activity. The bone is also hypocellular 
with regions of empty lacunae devoid of osteocytic nuclei. There may be attempts at healing 
demonstrated by reparative granulation tissue and some degree of new osteoid deposition. 
Histological features of osteonecrosis are similar in the oral and non-oral bone and are 
independent of the bone type.
4. Radiological features of osteonecrosis
Radiological features of osteonecrosis must be correlated with histological findings. A good 
starting point for diagnosis of osteonecrosis is the use of plain film and panoramic 
radiography (figure 2), cone beam computerized tomography (CBCT) (figure 3) 
conventional CT (figure 4). Plain film radiographs will display mixed radiolucent and 
radiopaque trabecular pattern. Depending on the cause of the osteonecrosis, there could be 
regions of osteolysis and sclerosis. Similarly, CT will display altered trabeculation, cortical 
thinning and sclerosis. Unfortunately, there needs to be about 30-50% loss of bone mineral 
content for a bone lesion to be better defined in a panoramic radiograph or CT 6.
Other limits of panoramic radiograph and CT are that some of the radiographic features are 
not specific to osteonecrosis; also these imaging modalities cannot differentiate necrotic 
bone from metastatic lesion especially in oncology patients where this may be a concern 38. 
Bone scintigraphy or bone scan provides better information about the metabolic activities 
and pathophysiological changes in osteonecrosis much earlier than panoramic radiograph as 
osteonecrosis will display high uptake of 99mTc-methylene diphosphonate in a bone scan. 
But a major diagnostic challenge of using bone scintigraphy to diagnose osteonecrosis is its 
high signal sensitivity and low specificity as many dental disorders can present as 
osteonecrosis in a bone scan.
The additional use of the combinations of fluorodeoxyglucose/positron emission 
tomography (FDG/PET) and single photon emission computed tomography (SPECT)/CT 
combination have also been shown to improve diagnostic accuracy because they provide 
functional and anatomic co-registration of the extent of the osteonecrosis 32, 39-41. Magnetic 
resonance imaging (MRI) can display osteonecrosis as decreased marrow signal intensity on 
T1-weighted images and increased signal intensity on T2-weighted images. Interestingly, 
studies using osteonecrosis of the hip samples have also shown that magnetic resonance 
imaging (MRI) findings correlate well with histological features of osteonecrosis 42. As 
MRI displays excellent visualization of soft tissues, it may be useful in the diagnosis of 
osteonecrosis in the mandibular condyle and around the TMJ complex where it may be 
clinically impracticable to obtain biopsy samples
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5. Conclusion
The role of radiographic imaging in diagnosis of osteonecrotic lesions cannot be 
overemphasized. However, there are limitations in the use of radiologic imaging only as the 
standard of diagnosis without correlating the findings with other aspects of diagnosis - 
clinical presentation and histologic findings. This is because most types of jaw osteonecrosis 
have similar radiographic presentations and cannot be differentiated from other diseases 
affecting the jaw bone e.g. osteomyelitis and periapical lesions.
Treatment options for jaw osteonecrosis includes the use of local and systemic antibiotics; 
pain medications; debriding; sequestrectomy; hyperbaric oxygen treatment; use of 
antioxidants-tocopherol and Pentoxifylline 43. Surgical resection is usually a last resort, 
when all other forms of therapy fail.
The effects on the quality of life in patients with jaw osteonecrosis, makes it an important 
area of research especially to researchers interested in bone and tissue engineering. An 
interesting area of ongoing research right now is the possible role of mesenchymal stem 
cells in possible reconstruction of the defect caused by jaw osteonecrosis and the use of 
pharmacologic compounds e.g. anti-sclerostin antibody in the prevention of the 
osteonecrotic process especially in patients with MRONJ 44-47.
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Key Points
• The role of radiographic imaging in diagnosis of osteonecrotic lesions cannot be 
overemphasized.
• Treatment options for jaw osteonecrosis includes the use of local and systemic 
antibiotics; pain medications; debriding; sequestrectomy; hyperbaric oxygen 
treatment; use of antioxidants-tocopherol and pentoxifylline. Surgical resection 
is usually a last resort, when all other forms of therapy fail.
• The effects on the quality of life in patients with jaw osteonecrosis, make it an 
important area of research especially to researchers interested in bone and tissue 
engineering.
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Fig 1. 
Intraoral photograph of a patient who received radiation therapy for oral cancer. Note the 
several complications of radiation therapy that include extensive caries involving multiple 
surfaces including incisal edges (arrow heads). The chalky white appearance of teeth is 
characteristic of radiation caries. Also note the angular cheilitis due to radiation induced 
xerostomia (arrow)
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Fig 2. 
Right premolar bitewing radiograph of a patient who received radiation therapy for head and 
neck cancer. Note the extensive carious lesions and failing restorations.
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Fig 3. 
Left premolar bitewing of the same patient as in fig 2 with evidence of extensive dental 
caries due to a combination of decreased salivation and increased biofilm.
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Fig 4. 
Osteoradionecrosis of the mandible. This patient received radiation therapy for head and 
neck cancer. The panoramic radiographs before radiation therapy (A) show intact and well 
corticated outline of the mandible. However, the patient developed left mandibular 
osteoradionecrosis (B, red arrow) after undergoing post-irradiation extraction of the left 
mandibular premolars.
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Fig 5. 
Exposed bone in the right mandibular posterior region in a patient with medication related 
osteonecrosis of the jaw.
Courtesy of Drs. Arthur Kuperstein DDS and Mel Mupparapu, DMD, University of 
Pennsylvania School of Dental Medicine.
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Fig 6. 
Panoramic reconstruction of the mandible and maxilla in a patient with medication related 
osteonecrosis of the jaw (arrow points to the area of osteonecrosis).
Courtesy of Drs. Arthur Kuperstein DDS and Mel Mupparapu, DMD, University of 
Pennsylvania School of Dental Medicine.
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Fig 7. 
Same patient as in figures 5 and 6. CBCT three dimensional reconstruction of the facial 
skeleton showing the separated osteonecrotic alveolar portion of the mandible (arrows 
heads).
Courtesy of Drs. Arthur Kuperstein DDS and Mel Mupparapu, DMD, University of 
Pennsylvania School of Dental Medicine.
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Table 1
Classification of ORN.
Adapted from Lyons A, Osher J, Warner E, Kumar R, Brennan PA. Osteoradionecrosis A review of current 
concepts in defining the extent of the disease and a new classification proposal. British Journal of Oral and 
Maxillofacial Surgery 2014 5;52(5):392; with permission.
Stage Length of affected 
bone/associated 
structures 
(damaged/
exposed)
Presence/absence of symptoms Treatment
1 <2.5cm Asymptomatic Medication treatment only
2 >2.5cm Asymptomatic.
Includes pathological fracture and/or involvement of 
inferior dental nerve.
Medication treatment only; except for presence 
of dental sepsis and loose/necrotic bone
3 >2.5cm Symptomatic.
No other features of bone necrosis. However, symptoms 
persist despite medication treatment.
Debridement of loose/necrotic bone.
Local pedicle flap
4 >2.5cm Symptomatic.
Pathological fracture. Involvement of Inferior alveolar 
nerve and/or orocutaneous fistula
Reconstruction with free flap, if patient's overall 
health allows
Dent Clin North Am. Author manuscript; available in PMC 2017 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Omolehinwa and Akintoye Page 20
Table 2
Implicated drugs in MRONJ and their mechanisms of action
Zoledronic acid Denosumab Bevacizumab
Half life Binds to bone-longer half life Does not bind to bone – short 
half- life (approx. 28 days)
Does not bind to bone – short 
half-life (approx. 20 days)
Mechanism Apoptosis of osteoclasts Prevents formation of 
osteoclasts
Inhibits angiogenesis
Target pathways/transcription proteins Inhibits Farnesyl 
Pyrophosphate (FPP) through 
mevalonate pathway
Inhibits Receptor activator of 
nuclear factor kappa-B ligand 
(RANKL)
Inhibits tyrosine kinase by 
binding to :Vascular 
Endothelial Growth Factor 
(VEGF)
Effects on immune system No effect on immune system Tendency to cause 
immunosuppression by action 
on B and T cells
Has effects on the immune 
system
Clearance Clearance through kidneys – 
nephrotoxic (up to 12 years)
Clearance through 
immunoglobulin pathway in 
reticuloendothelial system 
(within 6 months)
Clearance by pinocytosis 
with binding to neonatal Fc 
receptor 27
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Table 3
Clinical staging of MRONJ
Adapted from Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American 
association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 
2014 update. Journal of Oral and Maxillofacial Surgery 2014 9 March 2015;72(10):1938; with permission.
Clinical staging Presentation
Stage 0 Non- specific odontogenic symptoms in patients with a history of antiresorptive treatments
Stage 1 Asymptomatic bony exposure
Stage 2 Bony exposure, pain and infection, well contained in the dento-alveolar area
Stage 3 Stage 2 disease symptoms extending beyond the alveolar area. Includes pathological fractures, oroanthral communication, 
maxillary sinusitis, sinuses and fistula.
Dent Clin North Am. Author manuscript; available in PMC 2017 January 01.
